Paper40692147
Machine Learning, Virtual Screening and Bioactivity Evaluation to Identify AJ-292/12941271 as an Anti-proliferative Agent and Target mTOR Protein.
Li M and 6 others. Curr Med Chem, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Machine Learning, Virtual Screening and Bioactivity Evaluation to Identify AJ-292/12941271 as an Anti-proliferative Agent and Target mTOR Protein. Papers, record 40692147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40692147
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Machine Learning, Virtual Screening and Bioactivity Evaluation to Identify AJ-292/12941271 as an Anti-proliferative Agent and Target mTOR Protein.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| TOR Serine-Threonine Kinases | Major topic |
| Antineoplastic Agents | Major topic |
| Machine Learning | Major topic |
| MTOR Inhibitors | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Humans | |
| Cell Proliferation | |
| Drug Screening Assays, Antitumor | |
| Structure-Activity Relationship | |
| Molecular Docking Simulation | |
| Cell Line, Tumor | |
| Molecular Structure |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 2 | 36097292 | Isoform-resolved mRNA profiling of ribosome load defines interplay of HIF and mTOR dysregulation in kidney cancer. | Nat Struct Mol Biol | 2022 | https://conductscience.org/library/papers/36097292 | PubMed |
| 3 | 36010585 | PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer. | Cells | 2022 | https://conductscience.org/library/papers/36010585 | PubMed |
| 4 | 34279440 | Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products. | Molecules | 2021 | https://conductscience.org/library/papers/34279440 | PubMed |
| 5 | 24782981 | Targeting PI3K/Akt/mTOR Signaling in Cancer. | Front Oncol | 2014 | https://conductscience.org/library/papers/24782981 | PubMed |
| 6 | 32175074 | mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. | Cell Biosci | 2020 | https://conductscience.org/library/papers/32175074 | PubMed |
| 7 | 36442772 | mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53flox/+LSL-KrasG12D/+Pdx-1-Cre murine models. | Cancer Lett | 2023 | https://conductscience.org/library/papers/36442772 | PubMed |
| 8 | 25524385 | mTOR signaling, Tregs and immune modulation. | Immunotherapy | 2014 | https://conductscience.org/library/papers/25524385 | PubMed |
| 9 | 31408724 | mTOR: Role in cancer, metastasis and drug resistance. | Semin Cancer Biol | 2019 | https://conductscience.org/library/papers/31408724 | PubMed |
| 10 | 17545512 | The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17545512 | PubMed |
| 11 | 29523752 | Drug discovery targeting the mTOR pathway. | Clin Sci (Lond) | 2018 | https://conductscience.org/library/papers/29523752 | PubMed |
| 12 | 32416459 | Targeting mTOR for fighting diseases: A revisited review of mTOR inhibitors. | Eur J Med Chem | 2020 | https://conductscience.org/library/papers/32416459 | PubMed |
| 13 | 23983265 | Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis. | Proc Natl Acad Sci U S A | 2013 | https://conductscience.org/library/papers/23983265 | PubMed |
| 14 | 26810941 | New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation. | Br J Clin Pharmacol | 2016 | https://conductscience.org/library/papers/26810941 | PubMed |
| 15 | 22844270 | Pathophysiological insights into cardiovascular health in metabolic syndrome. | Exp Diabetes Res | 2012 | https://conductscience.org/library/papers/22844270 | PubMed |
| 16 | 36182721 | Sarcoidosis incidence after mTOR inhibitor treatment. | Semin Arthritis Rheum | 2022 | https://conductscience.org/library/papers/36182721 | PubMed |
| 17 | 29229111 | Toxicity risk from glucocorticoids in sarcoidosis patients. | Respir Med | 2017 | https://conductscience.org/library/papers/29229111 | PubMed |
| 18 | 35688004 | Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021). | Eur J Med Chem | 2022 | https://conductscience.org/library/papers/35688004 | PubMed |
| 19 | 30359003 | Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders. | J Med Chem | 2018 | https://conductscience.org/library/papers/30359003 | PubMed |
| 20 | 35164788 | m6A modification: recent advances, anticancer targeted drug discovery and beyond. | Mol Cancer | 2022 | https://conductscience.org/library/papers/35164788 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| PIK3CB | 5291 | PubTator's text mining | https://conductscience.org/library/genes/5291 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40692147
GET https://conductscience.org/api/papers/v1/40692147/references?page=2